Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Michael, Smyth, Elizabeth C, Cunningham, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/
https://www.ncbi.nlm.nih.gov/pubmed/27524910
http://dx.doi.org/10.2147/OTT.S84153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/
https://www.ncbi.nlm.nih.gov/pubmed/27524910
http://dx.doi.org/10.2147/OTT.S84153

Ejemplares similares